[go: up one dir, main page]

HK1150769A1 - Antibiotic compositions for treatment of the eye - Google Patents

Antibiotic compositions for treatment of the eye Download PDF

Info

Publication number
HK1150769A1
HK1150769A1 HK11104892.8A HK11104892A HK1150769A1 HK 1150769 A1 HK1150769 A1 HK 1150769A1 HK 11104892 A HK11104892 A HK 11104892A HK 1150769 A1 HK1150769 A1 HK 1150769A1
Authority
HK
Hong Kong
Prior art keywords
composition
ophthalmic
compositions
influenzae
use according
Prior art date
Application number
HK11104892.8A
Other languages
German (de)
English (en)
Chinese (zh)
Other versions
HK1150769B (en
Inventor
Gerald Cagle
Robert L. Abshire
David W. Stroman
John M. Yanni
Original Assignee
Alcon Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26799441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1150769(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Pharmaceuticals Ltd. filed Critical Alcon Pharmaceuticals Ltd.
Publication of HK1150769A1 publication Critical patent/HK1150769A1/en
Publication of HK1150769B publication Critical patent/HK1150769B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (9)

  1. Moxifloxacine ou hydrate ou sel de celle-ci pharmaceutiquement utile pour une utilisation dans le traitement ou la prévention topique des infections ophtalmiques associées à H. influenzae / β-lactamase positive ou H. influenzae / β-lactamase negative.
  2. Composition topique ophtalmique comprenant une quantité efficacement antimicrobienne de moxifloxacine ou d'un hydrate ou sel de celle-ci pharmaceutiquement utile et d'un excipient pharmaceutiquement acceptable pour une utilisation dans le traitement ou la prévention topique des infections ophtalmiques associées à H. influenzae / β-lactamase positive ou H. influenzae /β-lactamase negative.
  3. Composition pour une utilisation selon la revendication 2 comprenant de la moxifloxacine ou un hydrate ou sel de celle-ci pharmaceutiquement utile dans une concentration de 0,1 à 1,0 % en poids.
  4. Composition pour une utilisation selon l'une des revendications 2 ou 3, dans laquelle le traitement ou la prévention des infections ophtalmiques associées à H. influenzae / β-lactamase positive ou H. influenzae / β-lactamase negative comprend l'application topique d'une quantité thérapeutiquement efficace de la composition sur le tissu ophtalmique affecté.
  5. Composition pour une utilisation selon l'une des revendications 2 à 4, dans laquelle la composition comprend en outre une quantité efficacement anti-inflammatoire d'un agent anti-inflammatoire stéroïdien ou non-stéroïdien.
  6. Composition pour une utilisation selon la revendication 5, dans laquelle l'agent anti-inflammatoire comprend un glucocorticoïde.
  7. Composition pour une utilisation selon la revendication 6, dans laquelle le glucocorticoïde est choisi dans le groupe constitué de la dexaméthasone, de la rimexolone, de la prednisolone, de la fluorométholone, de l'hydrocortisone, de la mométasone, de la fluticasone, de la béclométhasone, du flunisolide, de la triamcinolone et du budésonide.
  8. Composition pour une utilisation selon la revendication 5, dans laquelle l'agent anti-inflammatoire comprend un agent non-stéroïdien choisi dans le groupe constitué des inhibiteurs de la prostaglandine H synthétase, des antagonistes de PAF et des inhibiteurs de PDE IV.
  9. Composition pour une utilisation selon la revendication 5, dans laquelle l'agent anti-inflammatoire comprend de la dexaméthasone.
HK11104892.8A 1998-09-30 2002-01-02 Antibiotic compositions for treatment of the eye HK1150769B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10250498P 1998-09-30 1998-09-30
US10250698P 1998-09-30 1998-09-30
US102506P 1998-09-30
US102504P 1998-09-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK04102444.4A Addition HK1059572B (en) 1998-09-30 2002-01-02 Antibiotic compositions containing moxifloxacin for treatment of the eye

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK04102444.4A Division HK1059572B (en) 1998-09-30 2002-01-02 Antibiotic compositions containing moxifloxacin for treatment of the eye

Publications (2)

Publication Number Publication Date
HK1150769A1 true HK1150769A1 (en) 2012-01-13
HK1150769B HK1150769B (en) 2015-06-19

Family

ID=

Also Published As

Publication number Publication date
JP2013018799A (ja) 2013-01-31
BRPI9914151B8 (fr) 2021-05-25
AR020661A1 (es) 2002-05-22
DE69912972D1 (de) 2003-12-24
HK1150756A1 (en) 2012-01-13
TR200704370T2 (tr) 2007-11-21
AU1310100A (en) 2000-04-17
CA2342211C (fr) 2009-05-26
ES2602956T3 (es) 2017-02-23
ATE501732T1 (de) 2011-04-15
EP1117401B1 (fr) 2003-11-19
JP5563041B2 (ja) 2014-07-30
JP2012067141A (ja) 2012-04-05
ES2526521T3 (es) 2015-01-13
EP2301541A1 (fr) 2011-03-30
ATE254458T1 (de) 2003-12-15
BRPI9914151B1 (pt) 2017-10-03
DK1117401T3 (da) 2004-02-23
DE69943287D1 (de) 2011-04-28
PT2269602E (pt) 2014-12-29
KR101463243B1 (ko) 2014-12-17
DK2269602T3 (en) 2014-12-15
DK2301541T3 (da) 2014-09-01
WO2000018386A3 (fr) 2000-06-08
CN1184968C (zh) 2005-01-19
JP2009007375A (ja) 2009-01-15
JP2014144982A (ja) 2014-08-14
PT1384478E (pt) 2011-05-12
WO2000018386A2 (fr) 2000-04-06
PT2301541E (pt) 2014-10-29
HK1038691A1 (en) 2002-03-28
TWI222361B (en) 2004-10-21
HK1059572A1 (en) 2004-07-09
EP2301541B1 (fr) 2014-08-20
EP1384478B1 (fr) 2011-03-16
PT2796138T (pt) 2016-09-22
EP2796138B1 (fr) 2016-08-17
HK1038691B (en) 2004-04-23
EP1384478A1 (fr) 2004-01-28
KR20010075138A (ko) 2001-08-09
AR081393A2 (es) 2012-08-29
CA2342211A1 (fr) 2000-04-06
PT1117401E (pt) 2004-03-31
CA2774207A1 (fr) 2000-04-06
JP2002525317A (ja) 2002-08-13
CN1650863A (zh) 2005-08-10
CY1111404T1 (el) 2015-08-05
EP2269602A1 (fr) 2011-01-05
CA2659064A1 (fr) 2000-04-06
DE69912972T2 (de) 2004-04-22
AU762827B2 (en) 2003-07-03
CY1115916T1 (el) 2017-01-25
CN100374114C (zh) 2008-03-12
TR200100883T2 (tr) 2001-10-22
CY1115759T1 (el) 2017-01-25
EP1117401A2 (fr) 2001-07-25
BR9914151A (pt) 2001-06-26
EP2269602B1 (fr) 2014-11-19
ES2207307T3 (es) 2004-05-16
DK1384478T3 (da) 2011-05-23
ES2519190T3 (es) 2014-11-06
CN1320035A (zh) 2001-10-31
EP2796138A1 (fr) 2014-10-29
DK2796138T3 (en) 2016-12-05

Similar Documents

Publication Publication Date Title
EP2301541B1 (fr) Compositions antibiotiques destinees au traitement des yeux
US8673902B2 (en) Method of treating otic infections with moxifloxacin compositions
US6395746B1 (en) Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
EP1117406A1 (fr) Compositions antibiotiques pour le traitement des yeux, des oreilles et du nez
AU2003248033B2 (en) Antibiotic Compositions for Treatment of the Eye, Ear and Nose
HK1150769B (en) Antibiotic compositions for treatment of the eye
HK1059572B (en) Antibiotic compositions containing moxifloxacin for treatment of the eye
ZA200101752B (en) Methods of treating or preventing ophthalmi infections with moxifloxacin.
HK1150756B (en) Antibiotic compositions for treatment of the ear
MXPA01003294A (en) Antibiotic compositions for treatment of the eye, ear and nose
AU2007201610A1 (en) Antibiotic compositions for treatment of the eye, ear and nose
MXPA01003293A (en) Antibiotic compositions for treatment of the eye, ear and nose
MXPA01003295A (en) Antibiotic compositions for treatment of the eye, ear and nose

Legal Events

Date Code Title Description
PE Patent expired